Novel insight into Y-box binding protein 1 in the regulation of vascular smooth muscle cell proliferation through targeting GC box-dependent genes  by Shi, Jian-hong et al.
FEBS Letters 587 (2013) 1326–1332journal homepage: www.FEBSLetters .orgNovel insight into Y-box binding protein 1 in the regulation of vascular
smooth muscle cell proliferation through targeting GC box-dependent
genes0014-5793/$36.00  2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.febslet.2013.02.047
Abbreviations: ATRA, all-trans-retinoic acid; ChIP, chromatin immunoprecipita-
tion; CSD, cold-shock domain; DMEM, Dulbecco’s modiﬁed Eagle’s medium; FBS,
fetal bovine serum; PCNA, proliferating cell nuclear antigen; PDGF, platelet-derived
growth factor; qRT-PCR, quantitative real-time RT-PCR; si-NS, non-speciﬁc siRNA;
siRNA, small interfering RNA; SM a-actin, smooth muscle a-actin; SRF, serum
response factor; VSMC, vascular smooth muscle cell; YB1, Y-box binding protein 1;
YB1-CTD, YB1 C-terminal tail domain
⇑ Corresponding author. Address: Department of Biochemistry and Molecular
Biology, The Key Laboratory of Neurobiology and Vascular Biology, China Admin-
istration of Education, Hebei Medical University, No. 361 Zhongshan East Road,
Shijiazhuang 050017, China. Fax: +86 311 86266180.
E-mail address: wjk@hebmu.edu.cn (J.-k. Wen).Jian-hong Shi a,b, Bin Zheng a, Yong-hui Li a, Yan Sun a, Ai-li Han a, Xin-hua Zhang a, Xin-rui Lv a, Si Chen a,
Jin-kun Wen a,⇑
aDepartment of Biochemistry and Molecular Biology, The Key Laboratory of Neurobiology and Vascular Biology, China Administration of Education, Hebei Medical University,
Shijiazhuang 050017, China
bClinical Medical College, Hebei University, Baoding 071000, Chinaa r t i c l e i n f o
Article history:
Received 24 January 2013
Revised 21 February 2013
Accepted 26 February 2013
Available online 13 March 2013
Edited by Ned Mantei
Keywords:
GC box
Proliferation
Vascular smooth muscle cell
Y-box binding protein 1a b s t r a c t
Abnormal proliferation of vascular smooth muscle cells (VSMCs) is a key event in atherosclerosis
and restenosis. In this paper, we report that Y-box binding protein 1 (YB1) functions as a phenotypic
regulator in VSMC proliferation-differentiation switching through targeting GC box-dependent
genes. Oligo pull-down assays demonstrated that YB1 binds directly to GC boxes via amino acids
125–220. YB1 C-terminal tail domain (CTD, amino acids 125–324) regulates GC box-dependent target
gene transcription and suppresses VSMC proliferation. These ﬁndings provide a novel insight into
the regulation of GC box-related genes by YB1, and provide a new understanding of VSMC prolifer-
ation regulation.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Y-box binding protein 1 (YB1) contains a highly conserved cold-
shock domain (CSD), and thus belongs to the CSD protein
superfamily, which has potential roles in a wide variety of cellular
functions including transcriptional regulation, RNA splicing, mRNA
translation, DNA repair and drug resistance [1]. YB1 is predomi-
nantly localized in the cytoplasm and moves into the nucleus in re-
sponse to cellular stress signals, including low temperature, drug
toxicity, reactive oxygen signaling, and DNA damage [1,2]. In the
nucleus, it regulates transcription of genes involved in proliferation
and differentiation [1]. For example, accumulation of YB1 in thenucleus is accompanied by transcriptional activation of cyclin A
and B1 genes and has been suggested as a marker of the aggres-
siveness of certain human cancers such as ovarian cancer [3].
YB1 is also known to promote cell proliferation through the trans-
activation of target genes such as proliferating cell nuclear antigen
(PCNA), epidermal growth factor, DNA topoisomerase II, thymidine
kinase [4], the B chain isoform of platelet-derived growth factor
[5], and vascular endothelial growth factor [6]. Besides promoting
cell proliferation, YB1 also regulates skeletal muscle differentiation
by interacting with Msx1 homeoprotein [3], but recent evidence
shows that YB1 is a potent repressor of vascular smooth muscle
a-actin (SM a-actin) gene transcription, a differentiation marker
of vascular smooth muscle cells (VSMCs), and can also bind SM
a-actin mRNA to regulate its translation [7].
YB1 was initially identiﬁed as a transcription factor that binds
to the speciﬁc DNA sequence containing the 50-CTGATTGG-30 motif
(so-called Y-box) or inverted CCAAT box, and regulates the expres-
sion of a large number of gene products in both positive and neg-
ative manners [1]. In addition, YB1 also binds to other motifs, such
as single-stranded DNA (ss-DNA, C/T- and GC/GA-rich sequences)
or AP-1 binding sites, and promotes or suppresses target gene tran-
scription [8]. Our previous data have shown that YB1 binds to
GGGCGG motif (known as GC box) in the proximal promoter of
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liferation in VSMCs [9]. Despite these advances, the mechanisms by
which YB1 regulates GC box-dependent gene expression are still
largely unknown. In this study, we sought to further investigate
the molecular mechanisms of YB1 interaction with GC boxes and
reveal the role of YB1 in VSMC phenotype switching.
2. Materials and methods
2.1. Cell culture
VSMCs were extracted from the thoracic aorta of male Sprague–
Dawley rats (90–100 g) as described previously [10]. VSMCs were
maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS; HyClone, Logan,
UT, USA) in a humidiﬁed atmosphere with 5% CO2 at 37 C. The
293A cells (Invitrogen, Carlsbad, CA, USA) were maintained in
high-glucose DMEM supplemented with 10% FBS.
2.2. Adenovirus expression vector and plasmid construction
The GST-YB1 plasmid was kindly provided by Dr. Kiyoshi Hig-
ashi (Sumitomo Chemical, Konohana-ku, Osaka, Japan); full-length
or truncated forms of GST- or GFP-tagged YB1 expression con-
structs were ampliﬁed from the human YB1 coding region by
PCR and cloned into the pGEX or pEGFP vector. For the adenovirus
expression vector, the GFP-YB1 or GFP-YB1 CTD coding region was
cloned into the pAD/CMV/V5-DEST vector (Invitrogen, Carlsbad,
CA, USA) to create the adenovirus pAd-GFP-YB1 or pAd-GFP-YB1
CTD. The resulting constructs were packaged in 293A cells. The
SM22a and p21 promoter reporter constructs have been described
previously [11,12]. The human cyclin D1 promoter reporter con-
struct was kindly provided by Dr. Alessandro Weisz (Seconda Uni-
versità degli Studi di Napoli, Naples, Italy).
2.3. Small interfering RNA (siRNA) transfection
Non-speciﬁc siRNA (si-NS) and a pool of 3 target-speciﬁc 20–
25 nt siRNAs targeting rat YB1 (si-YB1) were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Transfection was per-
formed using Lipofectamine reagent (Invitrogen, Carlsbad, CA,
USA) following the manufacturer’s instructions.
2.4. Oligo pull-down assay
Oligonucleotide pull-down assays were performed as described
previously [10]. Oligonucleotides containing the wild-type or mu-
tant GC box sequence with biotin added to their 50-end are shownTable 1
Sequences of biotinylated double-stranded oligonucleotides used
Gene Name Sequence
SM22a a tttttcccgccaccctc
a mut tttttcctttcaccctca
p21 b ggcgggagggggcg
b mut gtttggaggggtttgg
Cyclin D1 c acccccccacccccgc
c mut acccccccacccctttc
TbRI d gctggaccctgccccc
d mut gctggaccctgccccc
KLF4 e cgggaaggcggggag
e mut cgggaagaaagggag
f cgccacagggaggag
f mut cgccacagggaggag
AT1R g gaaaacttttaagggt
Cyclin E h ttcactgcagcacacc
CCL5 Y-box cattggtgcttggtcaa
GC probe 4  GC ggcgggggcgggggin Table 1. Cell extracts were precleared with ImmunoPure strepta-
vidin-agarose beads (20 lL/sample, Pierce, Rockford, IL, USA) and
then incubated with 100 pmol of biotinylated double-stranded oli-
gonucleotides and 10 lg of poly(deoxyinosine:deoxycytidine).
DNA-bound proteins were captured with 30 lL of immobilized
streptavidin-agarose beads; the bound proteins were separated
by SDS–PAGE and subjected to Western blotting with the indicated
antibodies.
2.5. Chromatin immunoprecipitation (ChIP) assay
ChIP assays were carried out as described previously [9]. Brieﬂy,
VSMCs were treated with 1% formaldehyde to cross-link proteins
with DNA. The cross-linked chromatin was then sonicated to an
average size of 400–600 bp. The DNA fragments were immunopre-
cipitated overnight with the anti-YB1 antibody. After reversal of
cross-linking, the genomic region of SM22a, p21 or cyclin D1 ﬂank-
ing the GC boxes was ampliﬁed by PCR with the following primer
pairs: SM22a (406–174), 50-GTCCCCTGCAAGCTCCTAAGA-30
(sense) and 50-AAGTTGGAGCAGTCTGTCGGG-30 (antisense); p21
(333–56), 50-TTCATAGATGTGCGTGGCTC-30 (sense) and 50-TTAA
CTCGGGCACTGTAGCA-30 (antisense); cyclin D1 (21–256), 50-CG
CTCTTTCCCAGCTTAGA-30 (sense) and 50-CAACTTCAACAAAACTCCC
CT-30 (antisense).
2.6. Western blotting
Crude proteins were extracted from VSMCs, resolved by SDS–
PAGE, and transferred onto a polyvinylidene diﬂuoride membrane
(Millipore, Billerica, MA, USA). After blocking with 5% non-fat milk
in TBST, membranes were immunoblotted with the following pri-
mary antibodies purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA): rabbit anti-GST, mouse anti-GFP, rabbit anti-cyclin
D1, rabbit anti-PCNA or mouse anti-b-actin. Additional primary
antibodies were purchased from Abcam (Abcam, Cambridge,
MA): rabbit anti-YB1, rabbit anti-SM22a, and rabbit anti-p21. After
incubation with the appropriate secondary antibody, the immuno-
reactive signals of antibody-antigen were visualized using the
Chemiluminescence Plus Western Blot analysis kit (Santa Cruz).
2.7. Luciferase assay
VSMCs were transfected with promoter reporter plasmids or
the control reporter plasmid pRL-TK using Lipofectamine 2000 re-
agent (Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. Twenty-four hours after transfection, cells
were lysed and luciferase assays were performed using a
dual-luciferase assay kit (Promega, Madison, WI, USA). Speciﬁcin oligo pull-down assay.
Bind
agcaccgcc
p
gcaccgcc
gggtcgggagngggggcggggccaggccgatg
p
gtcgggagnggggtttgggccaggccgatg
cgctcactgctc
p
gctcactgctc
acccgccggtagagta
p
atttgccggtagagta
aagaaaggcagggggcggggcctggcggcggag
p
aagaaaggcaggggtttgggcctggcggcggag
gcggggagcaagcgagcgag
p
aaagggagcaagcgagcgag
gatttagggaact
ccattcactcctg
agaggaaactgatgagctcactcagatctgc
p
cgggggcggg
p
Fig. 1. YB1 binds to GC-boxes of differentiation- and proliferation-related genes.
Oligo pull-down assays were performed with VSMC extracts (A), GFP-YB1-trans-
fected 293A cell lysates (B) or puriﬁed GST-YB1 (C) biotin-labeled double-stranded
oligonucleotides containing GC-boxes or their mutants were used as probes
(sequences shown in Table 1). The letters a–h for each lane refer to the
oligonucleotides depicted in Table 1; a, SM22a; b, p21; c, cyclin D1; d, TbRI; e,
and f, KLF4; g, AT1R; h, cyclin E. The DNA-bound proteins were collected with
streptavidin-agarose beads and analyzed by Western blotting with YB1, GFP, or GST
antibody.
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ﬁreﬂy luciferase to Renilla luciferase. All promoter constructs were
evaluated in P3 separate wells per experiment.
2.8. RNA preparation and quantitative real-time RT-PCR (qRT-PCR)
Total RNA was isolated with TRIzol reagent (Invitrogen) accord-
ing to the manufacturer’s instructions. qPCR of SM22a, p21, cyclin
D1 and PCNA were performed using Platinum SYBR Green qPCR
SuperMix UDG Kit (Invitrogen). GAPDH primers were used for
RNA template normalization. The primers used are available upon
request.
2.9. BrdU incorporation assay
DNA synthesis was assessed by bromodeoxyuridine (BrdU)-
incorporation assay using a commercially available ELISA kit (Mil-
lipore, Bedford, MA). The absorbance was measured in a Thermo
Fluroscan Ascent spectrophotometer at 450 nm.
2.10. Cell migration assay
The cell-wounding assay and modiﬁed Boyden transwell migra-
tion assay were performed as described previously [13,14]. The
migration activity of the cells was expressed as the number of mi-
grated cells in each ﬁeld under the microscope and expressed as
the percentage of control.
2.11. Immunoﬂuorescent staining and actin cytoskeleton staining
VSMCs were ﬁxed in 4% paraformaldehyde and permeabilized
with 0.1% Triton X-100, incubated with anti-YB1 antibody, and fur-
ther stained with FITC-conjugated secondary antibody or TRITC-
phalloidin. Staining of 40,6-diamidino-2-phenylindole (DAPI) was
used to visualize nuclear localization. Confocal microscopy was
performed with the Confocal Laser Scanning Microscope Systems
(Leica).
2.12. Statistical analysis
Data presented as bar graphs are the mean ± standard error of
the mean (S.E.M.) ofP3 independent experiments. Statistical anal-
yses were performed using Student’s t-test or one-way ANOVA
according to the number of groups compared. The results were
considered statistically signiﬁcant at P < 0.05.
3. Results
3.1. YB1 binds to the GC boxes of differentiation- and proliferation-
related genes
Because YB1 is known to regulate proliferation and differentia-
tion depending on the cellular context [1], we sought to determine
if YB1 binds directly to the GC boxes which are present in the pro-
moters of various differentiation- and proliferation-related genes.
Thus, we designed various biotinylated double-stranded probes
harboring GC box sequences, negative control probes containing
CACCC motif sequences, and probes containing mutated GC boxes
(Table 1). In addition, a Y-box probe and a 4  GC probe were de-
signed as positive controls (Table 1). Lysates of VSMC, GFP-YB1-
transfected 293A cells, or puriﬁed GST-YB1 were incubated with
the various probes and oligo pull-down assays were performed
to examine binding activity of YB1 to GC boxes. As shown in
Fig. 1, endogenous YB1, as well as overexpressed GFP-YB1 in
293A cells or puriﬁed GST-YB1, were associated with variousprobes containing GC boxes, including those from promoters of a
differentiation-related gene (SM22a), a negative cell cycle regula-
tor (p21) and a positive cell cycle regulator (cyclin D1). In all cases
mutation of the GC box sequence interrupted its binding activity.
The strongest binding was observed when the 4  GC-probe was
used. These results suggest that YB1 directly binds to GC box se-
quences of differentiation- and proliferation-related genes.
3.2. YB-1 mediates ATRA-induced VSMC differentiation by targeting GC
boxes
In a previous study we found that all-trans-retinoic acid (ATRA)
promoted the interaction of YB1 with the GC box of the Klf4 gene
promoter [9]. To examine if the increased binding of YB1 to the GC
box was related to its phosphorylation level, we assessed the effect
of ATRA on YB1 phosphorylation. ATRA increased YB1 phosphory-
lation within 10 min, and reached a maximun at 20 min (3.9-fold,
Fig. 2A). Nuclear translocation of YB1 induced by ATRA was also
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revealed that, although the majority of YB1 was retained in the
cytoplasm, ATRA treatment enabled more YB1 to translocate to
the nucleus in VSMCs (Fig. 2B and C).
To investigate whether ATRA affects the binding activity of YB1
to the GC boxes from different gene promoters in VSMCs, we car-
ried out an oligo pull-down assay (Fig. 2D). ATRA stimulation sig-
niﬁcantly promoted the binding of YB1 to the GC box probes a
and b (corresponding to the VSMC differentiation marker SM22a
and the negative cell cycle regulator p21) but not probe c (positive
cell cycle regulator, cyclin D1). Consistent with the results of the
oligo pull-down assay, the ChIP assay showed that the binding of
YB1 to the SM22a or p21 promoter region spanning the GC box
was increased by ATRA stimulation, but ATRA treatment did not af-
fect the binding of YB1 to the cyclin D1 promoter (Fig. 2E).
We next knocked down endogenous YB1 using si-RNA targeting
YB1 (si-YB1) in VSMCs, and overexpressed YB1 by infecting VSMCs
with Ad-GFP-YB1, to examine the role of YB1 in SM22a, p21 or cy-
clin D1 expression. Western blotting showed that ATRA signiﬁ-
cantly increased SM22a and p21 expression, and remarkably
decreased the cyclin D1 expression level (Fig. 2F andG). KnockdownFig. 2. YB1 mediates ATRA-induced VSMC differentiation by targeting GC boxes. (A) VSM
Cell extracts were immunoprecipitated with anti-phosphoserine antibody and analyzed b
b-actin in lysates are shown below. (B) VSMCs were treated with 10 lM ATRA for 2 h and
antibody. (C–E) VSMCs were treated with 10 lM ATRA for 2 h. (C) Cells were simultaneou
Magniﬁcation 400. (D) Oligo pull-down assays were performed with VSMC extracts from
promoter) and c (cyclin D1 promoter; a–c sequences shown in Table 1), and analyzed byW
or non-immune IgG as negative control. Immunoprecipitated DNA was ampliﬁed by PCR
24 h (F), or infected with Ad-GFP or Ad-GFP-YB1 for 24 h (G), and then treated with 10 l
antibodies. b-Actin was used as loading control.of YB1 abolished induction of SM22a and p21 expression by ATRA,
and abrogated ATRA-elicited suppression of cyclin D1 expression
(Fig. 2F). In contrast, overexpression of YB1 further enhanced the
induction of SM22a and p21 by ATRA and suppression of cyclin
D1 by ATRA (Fig. 2G). These results suggest that ATRA induces or re-
presses YB1 recruitment to the GC boxes of differentiation- and pro-
liferation-related genes in VSMCs, and that YB1 functions as an
activator or suppressor depending on gene context.
3.3. The interaction of YB-1 with GC boxes is independent of its Cold
Shock Domain (CSD) or ss-DNA binding region
To identify the speciﬁc regions in YB1 protein that are necessary
for GC box binding, we prepared and puriﬁed wt and truncated
GST-tagged YB1, and incubated with biotinylated double-stranded
probe a (SM22a promoter) in equal amounts followed by oligo
pull-down assay. Besides the full-length wt GST-YB1 (amino acids
1–324), probe a retained GST-YB1 (amino acids 1–220) and GST-
YB1 (amino acids 125–324) (Fig. 3B). Puriﬁed GST-YB1 (amino
acids 125–220) directly bound to probe a and the 4  GC probe
in a concentration-dependent manner (Fig. 3C). Similarly, theCs were treated with 10 lM ATRA (Sigma–Aldrich, St. Louis, MO, USA) for 0–40 min.
y Western blotting with YB1 antibody. ⁄P < 0.05 vs. the control group. Total YB1 and
then cytoplasmic and nuclear extracts were subjected to Western blotting with YB1
sly stained for YB1 (green) and DAPI (purple) and observed by confocal microscopy.
cells treated or not with ATRA (10 lM, 2 h) and probes a (SM22a promoter), b (p21
estern blotting with YB1 antibody. (E) ChIP assay was performed with YB1 antibody
using primers as indicated. (F, G) VSMCs were transfected with si-YB1 or si-NS for
M ATRA for 24 h. Cell lysates were analyzed by Western blotting with the indicated
1330 J.-h. Shi et al. / FEBS Letters 587 (2013) 1326–1332full-length wt GFP-YB1 or various truncated GFP-tagged YB1 were
transfected into 293A cells and the cell lysates were used to per-
form oligo pull-down assays using the 4  GC probe (Fig. S1).
Full-length GFP-YB1, GFP-YB1 (amino acids 125–220) and GFP-
YB1 (amino acids 125–324) could all bind the 4  GC probe. Taken
together, we conclude that the interaction of YB1 with GC boxes is
does not depend on the CSD (amino acids 65–125) or ss-DNA bind-
ing region (amino acids 15–71), and that the region between amino
acids 125 and 220 in YB1 is necessary and sufﬁcient for GC box
binding.
3.4. YB1 CTD regulates GC box-dependent target gene transcription
and suppresses VSMC proliferation
Because binding of YB1 to GC boxes did not depend on its CSD
or ss-DNA binding region, we sought to determine whether the
YB1 C-terminal tail domain (YB1 CTD, amino acids 125–324) is re-
quired for the transactivation of GC-dependent target genes.
VSMCs were co-transfected with a SM22a, p21 or cyclin D1 pro-
moter-reporter construct and GFP-YB1 or GFP-YB1 CTD expression
plasmid (Fig. 4A). Although YB1 overexpression could modestly in-
crease SM22a promoter transcription, YB1 CTD overexpression sig-
niﬁcantly elevated both SM22a and p21 promoter activities. In
contrast, both YB1 and YB1 CTD overexpression decreased cyclinFig. 3. The amino acids 125–220 are necessary and sufﬁcient for the interaction of
YB1 with GC boxes. (A) A schematic representation of wt and truncated GST- or
GFP-tagged YB1 structures. (B, C) Oligo pull-down assays were performed with
puriﬁed wt and truncated GST-YB1 and the indicated probes (sequences shown in
Table 1), and analyzed by Western blotting with GST antibody. Panel C shows the
dependence on concentration of fusion protein.D1 promoter activity. To further investigate this effect, adenovirus
expression vectors harboring GFP-tagged YB1 or YB1 CTD were
constructed and infected into VSMCs. Compared with Ad-GFP-in-
fected cells, overexpression of YB1 or YB1 CTD signiﬁcantly in-
creased SM22a and p21 mRNA and protein levels while
decreasing cyclin D1 and PCNA levels (Fig. 4B and C). Comparing
YB1 with YB1 CTD, YB1 CTD showed a higher transactivation or
transrepression capacity.
To further identify the potential role of YB1 CTD in VSMC prolif-
eration, VSMCs were infected for 72 h with Ad-GFP, Ad-GFP-YB1 or
Ad-GFP-YB1 CTD. The full-length form of YB1 was located in both
cytoplasm and nucleus with a speckled distribution in the majority
of cells, whereas YB1 CTD was located in the nucleus. Phalloidin
staining showed that the actin ﬁlaments were recruited into thick
and long actin bundles in YB1-overexpressing VSMCs; VSMCs over-
expressing YB1 CTD markedly elongated, with increased formation
of thick stress ﬁbers aligned along the long axis (Fig. 4D). Next,
BrdU incorporation assays were performed to examine the effects
of YB1 and YB1 CTD on VSMC proliferation. Knockdown of YB1 sig-
niﬁcantly increased cell proliferation, whereas YB1 or YB1 CTD
overexpression resulted in marked proliferation inhibition
(Fig. 4E). Moreover, knockdown of endogenous YB1 effectively en-
hanced the migratory activity of VSMCs, whereas in contrast, over-
expression of YB1 or YB1 CTD signiﬁcantly suppressed VSMC
migration as assessed by Boyden chamber or wound-healing cell
migration assays (Fig. 4F and Fig. S2).
4. Discussion
VSMCs in mature animal vessels are mainly differentiated cells
that express smooth muscle-speciﬁc contractile genes, SM a-actin
and SM22a, and negative cell cycle regulators, p21 and p27
[10,11,15,16]. In response to vascular injury, VSMCs revert to a
proliferative state coupled with cell cycle progression, which is
promoted by cyclins (e.g., cyclin D1 and cyclin E) [17]. Phenotypic
switching of VSMCs is a key event in the development of athero-
sclerosis and restenosis. Previous studies have shown that VSMC
proliferation and differentiation are tightly regulated by serum re-
sponse factor (SRF), the SRF coactivator myocardin, and KLF4/KLF5
[18,19]. Our recent observations showed that YB1 binds to GC
boxes in the proximal promoter of Klf4 and transactivates Klf4
gene expression in VSMCs [9]. In the present study, we sought to
reveal the role of YB1 in VSMC proliferation and differentiation
regulation, and the molecular mechanism of YB1 association with
GC box. The GC box is considered as a major controlling sequence
for transcription of a large number of genes, and notablely inter-
acts with zinc-ﬁnger transcriptional factors. Here, we ﬁrst reported
that YB1 binds to double stranded GC boxes via the region com-
prising amino acids 125–220, and that YB1 inhibits VSMC growth.
We designed various biotinylated double-stranded probes har-
boring GC box sequences from differentiation- and proliferation-
related genes to investigate the binding activity of YB1 to GC box
sequence from the different genes. YB1 physically bound to various
probes containing GC boxes in vitro, including probes from pro-
moters of the VSMC differentiation marker gene (SM22a), the neg-
ative cell cycle regulator (p21), and the positive cell cycle regulator
(cyclin D1). The strongest binding was observed when the 4  GC-
probe was used, which suggests that the association of YB1 with
GC boxes is direct and speciﬁc. Truncation analysis showed that
the interaction of YB1 with GC boxes is independent of the CSD
and ss-DNA binding regions of YB1. The amino acid 125–220 re-
gion is necessary and sufﬁcient for the binding activity, which re-
quires a GC probe.
Phenotypic switching of VSMCs is a key event in the develop-
ment of atherosclerosis and restenosis [13,19]. Therefore,
Fig. 4. YB1 CTD regulates GC box-dependent gene transcription and suppresses VSMC proliferation. (A) VSMCs were co-transfected for 24 h with SM22a, p21 or cyclin D1
promoter-reporter plasmid, as well as GFP-YB1 or GFP-YB1 CTD (amino acids 125–324) expression plasmid. Cell lysates were subjected to luciferase activity assays. Bars
represent the mean ± S.E.M. from 3 independent experiments. ⁄P < 0.05 vs. the respective control group. Expression of GFP, GFP-YB1, GFP-YB1 CTD was assessed by Western
blotting. b-Actin was the loading control. (B, C) VSMCs were infected with Ad-GFP (1), Ad-GFP-YB1 (2) or Ad-GFP-YB1 CTD (3) for 48 h. (B) The cell lysates were analyzed by
Western blotting with the indicated antibodies and b-actin was the loading control; (C) total RNA was isolated and subjected to qRT-PCR; bars represent the mean ± S.E.M.
from 3 independent experiments. (D) VSMCs were infected with Ad-GFP, Ad-GFP-YB1 or Ad-GFP-YB1 CTD for 72 h and then stained for F-actin with TRITC-phalloidin. Pictures
show the GFP-tag (green), Phalloidin (red) and DAPI (purple). Magniﬁcation 400. (E, F) VSMCs were transfected with si-NS or si-YB1, or infected with Ad-GFP, Ad-GFP-YB1 or
Ad-GFP-YB1 CTD for 48 h. (E) VSMC proliferation was tested using the BrdU incorporation assay kit (Millipore) and expressed as percentage of incorporation in the control
group. (F) Effects of YB1 or YB1 CTD on VSMC transwell migration were examined using the Boyden chamber assay. ⁄P < 0.05 vs. si-NS-transfected group, #P < 0.05 vs. Ad-GFP-
infected group.
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phenotype is helpful for the treatment of vascular remodeling dis-
eases. ATRA, as a potential anti-proliferative and a differentiation-
promoting agent in VSMCs [10,12], induced the recruitment of YB1
to GC boxes in the proximal Klf4 promoter and modulated Klf4
transcription. Thus, we speculated that YB1 could exert a potential
role during VSMC differentiation. In the present study, we showed
that ATRA induces YB1 phosphorylation and nuclear translocation,
and that YB1 participates in ATRA-induced VSMC differentiation.Adenovirus expression vectors harboring GFP-tagged YB1 or YB1
CTD were designed and infected into VSMCs. Overexpression of
YB1 CTD, which contains the GC box binding region but deletes
the CSD and ss-DNA binding regions, resulted in the formation of
thick stress ﬁbers and decreased the migration activity in cultured
VSMCs.
Abnormal proliferation of VSMCs in neointima formation and
vascular diseases is strongly related to cell cycle progression,
which is inhibited by cyclin-dependent kinase inhibitors (e.g.,
1332 J.-h. Shi et al. / FEBS Letters 587 (2013) 1326–1332p21 and p27), and is coupled with downregulation of VSMC differ-
entiation markers (e.g., SM22a and SMa-actin) [15,16]. In the pres-
ent study, Western blotting and qRT-PCR showed that the
expression of differentiation marker gene SM22a and negative cell
cycle regulator p21 were upregulated, and the expression of the
proliferation-related gene PCNA was downregulated in YB1 CTD-
overexpressing VSMCs, suggesting potential roles of YB1-CTD in
modulating the VSMC phenotype and preventing vascular diseases.
In summary, we ﬁrst reported that YB1 interacts with double
stranded GC boxes and plays an important role in promoting VSMC
differentiation and inhibiting VSMC proliferation. The present re-
sults describe a novel mechanism of regulation of transcription
of GC box-related genes by YB1, which is critical towards under-
standing the molecular mechanisms of VSMC differentiation.
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